AstraZeneca Pharma India could maintain its upward trajectory after surpassing its former swing high of ₹9,200, according to Finversify. They believe the stock may extend its rally and identified ₹7,810 as key support. Stock prices rose by 8% following the company's announcement of a 47.7% annual increase in fourth-quarter (Q4) net profit, reaching ₹58.2 crore.